# US 2004/0018974 A1 · Multivalent constructs for therapeutic and diagnostic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018974 A1
- Document ID: US20040018974A1
- Status: Published application
- Kind: A1
- Application number: 10/379,287
- Filed: 2003-03-03
- Published: 2004-01-29
- Earliest claimed: 2002-03-01
- Assignees: Bracco International B.V.; Dyax Corp.
- Inventors: Christophe Arbogast; Philippe Bussat; Hong Fan; Karen E. Linder; Edmund R. Marinelli; Palaniappa Nanjappan; Adrian Nunn; Radhakrishna Pillai; Sibylle Pochon; Kondareddiar Ramalingam; Ajay Shrivastava; Bo Song; Rolf E. Swenson; Mathew A. Von Wronski; Aaron Sato; Sharon Michele Walker; Daniel T. Dransfield
- Web page: https://patentgrep.com/patent/US20040018974A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 35/00: Antineoplastic agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides compositions and methods for therapeutic and diagnostic applications.

## Claims

### Claim 1

A multivalent compound comprising at least two binding moieties having specificity for different binding sites on the same target.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is a multimeric compound comprising a plurality of binding moieties.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is a dimeric compound.

### Claim 4 (depends on 1)

The compound of claim 1, wherein at least one of the binding moieties comprises a polypeptide.

### Claim 5 (depends on 4)

The compound of claim 4, wherein all of the binding moieties comprise polypeptides.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the affinity of the compound for the target is about 60 fold greater than the affinity of any one of the polypeptides for the target.

### Claim 7 (depends on 5)

The compound of claim 5, wherein the affinity of the compound for the target is about 560 fold greater than the affinity of any one of the polypeptides for the target.

### Claim 8 (depends on 4, 5)

The compound of claim 4 or 5, wherein each polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 9 (depends on 4, 5)

The compound of claim 4 or 5, wherein each polypeptide is selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27, SEQ NO:28, and SEQ ID NO:29

### Claim 10 (depends on 8, 9)

The compound of claim 8 or 9, wherein the polypeptide comprises an amino acid substitution, and amide bond substitution, a D-amino acid substitution, a glycosylated amino acid, a disulfide mimetic substitution, an amino acid translocation, a retroinverso peptide, a peptoid, a retro-inverso peptoid, or a synthetic peptide.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the target is a protein

### Claim 12 (depends on 1)

The compound of claim 1, wherein the target is a receptor or a receptor/ligand complex.

### Claim 13 (depends on 11)

The compound of claim 11, wherein the binding moieties bind to different epitopes on the protein.

### Claim 14 (depends on 12)

The compound of claim 12, wherein the binding moieties bind to different epitopes on the receptor or receptor/ligand complex.

### Claim 15 (depends on 11)

The compound of claim 11, wherein said target is a receptor involved in angiogenesis.

### Claim 16 (depends on 12)

The compound of claim 12, wherein said receptor is a protein-tyrosine kinase receptor.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the target comprises KDR or KDR/VEGF complex.

### Claim 18 (depends on 17)

The compound of claim 17, wherein the binding moieties bind to different epitopes on KDR or KDR/VEGF complex.

### Claim 19 (depends on 11)

The compound of claim 11, wherein said target is a receptor involved in hyperproliferation.

### Claim 20 (depends on 11)

The compound of claim 11, wherein said target is a receptor expressed on a tumor.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the target comprises hepatocyte growth factor (HGF) receptor (cMet) or HGF/cMet complex.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the binding moieties bind to different epitopes on cMet or the HGF/cMet complex.

### Claim 23 (depends on 22)

Th compound of claim 22, wherein the binding moieties comprise polypeptides.

### Claim 24 (depends on 18)

The compound of claim 18, wherein the binding moieties are selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 25 (depends on 18)

The compound of claim 18, wherein the binding moieties comprise SEQ ID NO:4 and SEQ ID NO:5.

### Claim 26 (depends on 22)

The compound of claim 22, wherein the binding moieties are selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27, SEQ NO:28, and SEQ ID NO:29.

### Claim 27 (depends on 1)

The compound of claim 1, further comprising at least one labeling group or therapeutic agent.

### Claim 28 (depends on 27)

The compound of claim 27, wherein the target comprises KDR or KDR/VEGF complex.

### Claim 29 (depends on 28)

The compound of claim 28, wherein the binding moieties bind to different epitopes on KDR or KDR/VEGF complex.

### Claim 30 (depends on 29)

The compound of claim 29, wherein the target comprises the hepatocyte growth factor (HGF) receptor (cMet) or HGF/cMet complex.

### Claim 31 (depends on 30)

The compound of claim 30, wherein the binding moieties bind to different epitopes on cMet or the HGF/cMet complex.

### Claim 32 (depends on 27)

The compound of claim 27, wherein the binding moieties comprise the sequence SEQ ID NO:8 and SEQ ID NO:9.

### Claim 33 (depends on 27)

The compound of claim 27, wherein the binding moities comprise the sequence SEQ ID NO:4 and SEQ ID NO:5.

### Claim 34 (depends on 27)

The compound of claim 27, wherein the binding moieties are selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27, SEQ NO:28, and SEQ ID NO:29.

### Claim 35 (depends on 27)

The compound of claim 27, wherein the labelling group or therapeutic agent comprises one or more paramagnetic metal ions or superparamagnetic particles, an ultrasound contrast agent, one or more photolabels, or one or more radionuclides.

### Claim 36 (depends on 35)

The compound of claim 35, wherein the paramagnetic metal ion is selected from Mn2+, Cu2+, Fe2+, Co2+, Ni2+, Gd3+, Eu3+, Dy3+, Pr3+, Cr3+, Co3+, Fe3+, Ti3+, Tb3+, Nd3+, Sm3+, Ho3+, Er3+, Pa4+, and Eu2+.

### Claim 37 (depends on 35)

The compound of claim 35, further comprising a chelator, wherein the chelator is 1-substituted 1,4,7,-tricarboxymethyl 1,4,7,10 teraazacyclododecane triacetic acid (DO3A).

### Claim 38 (depends on 35)

The compound of claim 35, further comprising gadolinium (III).

### Claim 39 (depends on 35)

The compound of claim 35, wherein the ultrasound contrast agent comprises a phospholipid stabilized microbubble or a microballoon comprising a fluorinated gas.

### Claim 40 (depends on 35)

The compound of claim 35, wherein the labeling group or therapeutic agent further comprises a chelator.

### Claim 41 (depends on 40)

The compound of claim 40, wherein the chelator comprises DTPA, DOTA, EDTA, TETA, EHPG, HBED, NOTA, DOTMA, TETMA, PDTA, TTHA, LICAM, or MECAM.

### Claim 42 (depends on 40)

The compound of claim 40, wherein the chelator comprises diethylenetriamine pentaacetic acid, tetraazacyclododecane triacetic acid, or a carboxymethyl-substituted derivative thereof.

### Claim 43 (depends on 35)

The compound of claim 35, where the radionuclide is 18F, 124I, 125I, 131I, 123I, 77Br, 76Br, 99mTc, 51Cr, 67Ga, 68Ga, 47Sc, 51Cr, 67Tm, 141Ce, 111In, 168Yb, 175Yb, 140La, 90Y, 88Y, 153Sm, 166H, 165Dy, 166Dy, 62Cu, 64Cu, 67Cu, 97Ru, 103Ru, 186Re, 188Re, 203Pb, 211Bi, 212Bi, 213Bi, 214Bi, 105Rh, 109Pd, 117mSn, 149Pm, 161Tb, 177Lu, 198Au or 199Au.

### Claim 44 (depends on 43)

The compound of claim 43, further comprising a compound having a structure selected from the following:
55

### Claim 45 (depends on 43)

The compound of claim 43, further comprising a compound having a structure selected from the following:
56
where X is CH2 or O;
Y is C1-C10 branched or unbranched alkyl, aryl, aryloxy, arylamino, arylaminoacyl, or aralkyl comprising C1-C10branched or unbranched alkyl groups, C1-C10 branched or unbranched hydroxy or polyhydroxyalkyl groups or polyalkoxyalkyl or polyhydroxy-polyalkoxyalkyl groups;
J is C(═O)—, OC(═O)—, SO2—, NC(═O)—, NC(═S)—, N(Y), NC(═NCH3)—, NC(═NH)—, N═N—, a homopolyamide or a heteropolyamine derived from synthetic or naturally occurring amino acids;
and n is 1-100.

### Claim 46 (depends on 43)

The compound of claim 43, further comprising a compound having the following structure:
57

### Claim 47 (depends on 44, 45)

The compound of claim 44 or 45, further comprising 99mTc, 186Re, or 188Re.

### Claim 48 (depends on 46)

The compound of claim 46, further comprising 99mTc.

### Claim 49 (depends on 43)

The compound of claim 43, further comprising a compound having the following structure:
58
where R is an alkyl group.

### Claim 50 (depends on 43)

The compound of claim 43, further comprising a compound having the following structure:
59
where R is an alkyl group.

### Claim 51 (depends on 43)

The compound of claim 43, further comprising a compound having the following structure:
60

### Claim 52 (depends on 49, 50, 51)

The compound of claim 49, 50 or 51, further comprising 177Lu, 90Y, 153Sm, 111In, or 166Ho.

### Claim 53 (depends on 27)

The compound of claim 27, further comprising a linker between a binding moiety and the labelling group or therapeutic agent.

### Claim 54

The compound of 53, wherein the linker comprises a substituted alkyl chain, an unsubstituted alkyl chain, a polyethylene glycol derivative, an amino acid spacer, a sugar, an aliphatic spacer, an aromatic spacer, a lipid molecule, or combination thereof.

### Claim 55 (depends on 27)

The compound of claim 27, wherein the therapeutic agent comprises a bioactive agent, a cytotoxic agent, a drug, a chemotherapeutic agent, or a radiotherapeutic agent.

### Claim 56 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer selected from D1, D4, D5, D6, D7, D10, D13, D17, D24, D26, and D31.

### Claim 57 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
61

### Claim 58 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
62

### Claim 59 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
63

### Claim 60 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
64

### Claim 61 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
65

### Claim 62 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
66

### Claim 63 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
67

### Claim 64 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
68

### Claim 65 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
69

### Claim 66 (depends on 1, 46)

A diagnostic imaging agent comprising a compound of any of claims 1, 46, or 47 conjugated to a microbubble or microballoon.

### Claim 67 (depends on 66)

The imaging agent of claim 66, wherein said microbubble or microballoon comprises a phospholipid comprising the formula:
70

### Claim 68 (depends on 66)

The imaging agent of claim 66, wherein said microbubble or microballoon comprises an biocompatible fluorinated gas selected from the group consisting of SF6, freons, and perfluorocarbons.

### Claim 69 (depends on 1, 53)

A diagnostic imaging method comprising the steps of:
(a) administering to a patient a pharmaceutical preparation comprising a compound according to any one of claims 1, 53, or 54; and
(b) imaging the compound after administration to the patient.

### Claim 70 (depends on 69)

The method of claim 69, wherein the imaging step comprises magnetic resonance imaging, ultrasound imaging, optical imaging, sonoluminescence imaging, photoacoustic imaging, or nuclear imaging.

### Claim 71 (depends on 69)

The method of claim 69, wherein the administering step comprises inhaling, transdermal absorbing, intramuscular injecting, subcutaneous injecting, intravenous injecting, or intraarterial injecting.

### Claim 72 (depends on 49, 50, 51, 52, 53, 54, 55)

A method of treating a disease, comprising the step of administering to a patient a pharmaceutical preparation comprising a compound of claim 49-55.

### Claim 73 (depends on 28, 29, 32, 33)

A method of treating a disease associated with angiogenesis, comprising the step of administering to a patient a pharmaceutical preparation comprising a compound of claim 28, 29 or 32-33.

### Claim 74 (depends on 31, 34)

A method of treating a disease associated with hyperproliferation, comprising the step of administering to a patient a pharmaceutical preparation comprising a compound of claim 31, 31 or 34.

### Claim 75 (depends on 73, 74)

The method of claim 73 or 74 wherein the disease is neoplastic tumor growth.

### Claim 76 (depends on 1)

A method of treating a disease comprising the step of administering to a patient a pharmaceutical preparation comprising a compound of claim 1.

### Claim 77

A method of screening for heteromultimeric compounds having improved binding affinity, the method comprising:
(a) preparing a labeled compound comprising at least two binding moieties that bind to different binding sites of a target;
(b) contacting the labeled compound with a target;
(c) determining a dissociation constant of the labeled compound; and
(d) comparing the dissociation constant of the labeled compound with the dissociation constant of one or more individual binding moieties.

### Claim 78 (depends on 77)

The method of claim 77, wherein said compound is a heteromultimeric compound comprising a plurality of binding moieties.

### Claim 79 (depends on 77)

The method of claim 77, wherein said compound is a heterodimeric compound.

### Claim 80 (depends on 77)

The method of claim 77, wherein at least one of the binding moieties comprises a polypeptide.

### Claim 81 (depends on 77)

The method of claim 77, wherein the target is a protein

### Claim 82 (depends on 77)

The method of claim 77, wherein the target is a receptor or a receptor/ligand complex

### Claim 83 (depends on 77)

The method of claim 77, wherein the binding moieties bind to different epitopes on the protein.

### Claim 84 (depends on 77)

The method of claim 77, wherein the binding moieties bind to different epitopes on the receptor or the receptor/ligand complex.

### Claim 85 (depends on 77)

The method of claim 77, wherein said target is a receptor involved in angiogenesis or hyperproliferation.

### Claim 86 (depends on 85)

The method of claim 85, wherein said receptor is a protein-tyrosine kinase receptor.

### Claim 87 (depends on 82)

The method of claim 82, wherein the target comprises KDR or VEGF/KDR complex.

### Claim 88 (depends on 87)

The method of claim 87, wherein the binding moieties bind to different epitopes n KDR or KDR/VEGF complex.

### Claim 89 (depends on 82)

The method of claim 82, wherein the target comprises hepatocyte growth factor (HGF) receptor (cMet) or HGF/cMet complex.

### Claim 90 (depends on 89)

The method of claim 89, wherein the binding moieties bind to different epitopes on cMet or the HGF/cMet complex.

### Claim 91 (depends on 77)

The method of claim 77, wherein at least one of the binding moieties comprises the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12.

### Claim 92 (depends on 77)

The method of claim 77, wherein the binding moieties comprise SEQ ID SEQ ID NO:26, SEQ ID NO:27, SEQ NO:28, or SEQ ID NO:29.

### Claim 93 (depends on 78)

The method of claim 78, further comprising the step of:
identifying a labeled heteromultimeric compound having a dissociation constant that is about twenty-fold less than the dissociation constant of a constituent binding moiety.

### Claim 94 (depends on 39)

The compound of claim 39, wherein the target is a receptor or a receptor/ligand complex.

### Claim 95 (depends on 94)

The compound of claim 94, wherein the binding moieties bind to different epitopes on the receptor or receptor/ligand complex.

### Claim 96 (depends on 95)

The compound of claim 95, wherein said target is a receptor involved in angiogenesis.

### Claim 97 (depends on 96)

The compound of claim 96, wherein said receptor is a protein-tyrosine kinase receptor.

### Claim 98 (depends on 97)

The compound of claim 97, wherein the target comprises KDR or KDR/VEGF complex.

### Claim 99 (depends on 98)

The compound of claim 98, wherein the binding moieties bind to different epitopes on KDR or KDR/VEGF complex.

### Claim 100 (depends on 95)

The compound of claim 95, wherein said target is a receptor involved in hyperproliferation.

### Claim 101 (depends on 96, 100)

The compound of claim 96 or 100, wherein said target is a receptor expressed on a tumor.

### Claim 102 (depends on 100)

The compound of claim 100, wherein the target comprises hepatocyte growth factor (HGF) receptor (cMet) or HGF/cMet complex.

### Claim 103 (depends on 95)

The compound of claim 95, wherein the binding moieties comprise polypeptides.

### Claim 104 (depends on 103)

The compound of claim 103, wherein the polypeptides are selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 105 (depends on 103)

The compound of claim 103, wherein the polypeptides are selrcted from the group consiting of SEQ ID NO:4 and SEQ ID NO:5.

### Claim 106 (depends on 103)

The compound of claim 103, wherein the polypeptides are selected from the group consisting of SEQ ID NO:26, SEQ ID NO:27, SEQ NO:28, and SEQ ID NO:29.

### Claim 107

A method of synthesizing a multimeric compound comprising at least two binding moieties having specificity for different binding sites on the same target, wherein at least one of the binding moieties comprises a cyclic polypeptide formed by introducing an amide bond between two side chains.

### Claim 108

A method of synthesizing a multimeric compound comprising at least two binding moieties having specificity for different binding sites on the same target, wherein at least one of the binding moieties comprises a polypeptide and a linker comprising at least one glycosylated amino acid selected from the group consisting or serine, threonine and homoserine.

### Claim 109

A method of synthesizing a multimeric compound comprising at least two binding moieties having specificity for different binding sites on the same target, selected from the group consisting of D1, D4, D5, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26 and D27, wherein the method comprises the steps set forth in Example 9.

### Claim 110 (depends on 3)

The compound of claim 3, wherein said compound comprises a dimer having the following formula:
71
